Is CRMD or BHC more profitable?

CorMedix has a net margin of 40.49% compared to Bausch Health Cos' net margin of -10.12%. CorMedix's return on equity of 40.52% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets CorMedix 40.49% 40.52% 20.61% Bausch Health Cos -10.12% -561.95% 6.31%

Which has stronger earnings and valuation, URGN or CRMD?

CorMedix has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urogen Pharma $109.79M 19.42 -$153.49M -$1.98 N/A CorMedix $311.71M 2.08 $163.05M $2.14 3.88

Is URGN or CRMD more profitable?

CorMedix has a net margin of 40.49% compared to Urogen Pharma's net margin of -51.73%. CorMedix's return on equity of 40.52% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Urogen Pharma -51.73% N/A -43.79% CorMedix 40.49% 40.52% 20.61%

CorMedix (CRMD) Competitors

$8.30 -0.01 (-0.12%)

As of 08/28/2026 04:00 PM Eastern

Compare

CRMD vs. OCUL, PBH, BHC, RAPP, and URGN

Should you buy CorMedix stock or one of its competitors? CorMedix's main competitors and comparable companies include Ocular Therapeutix (OCUL), Prestige Consumer Healthcare (PBH), Bausch Health Cos (BHC), Rapport Therapeutics (RAPP), and Urogen Pharma (URGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CorMedix compare to Ocular Therapeutix?

CorMedix (NASDAQ:CRMD) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

CorMedix has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CorMedix has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.08	$163.05M	$2.14	3.88
Ocular Therapeutix	$51.95M	43.80	-$265.94M	-$1.42	N/A

CorMedix has a net margin of 40.49% compared to Ocular Therapeutix's net margin of -579.10%. CorMedix's return on equity of 40.52% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

CorMedix presently has a consensus price target of $15.00, indicating a potential upside of 80.72%. Ocular Therapeutix has a consensus price target of $25.75, indicating a potential upside of 148.55%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Ocular Therapeutix had 13 more articles in the media than CorMedix. MarketBeat recorded 14 mentions for Ocular Therapeutix and 1 mentions for CorMedix. CorMedix's average media sentiment score of 0.94 beat Ocular Therapeutix's score of 0.70 indicating that CorMedix is being referred to more favorably in the media.

Company	Overall Sentiment
CorMedix	Positive
Ocular Therapeutix	Positive

Summary

CorMedix beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

How does CorMedix compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Prestige Consumer Healthcare has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.28	$190.30M	$3.57	14.70
CorMedix	$311.71M	2.08	$163.05M	$2.14	3.88

CorMedix has a net margin of 40.49% compared to Prestige Consumer Healthcare's net margin of 15.57%. CorMedix's return on equity of 40.52% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
CorMedix	40.49%	40.52%	20.61%

In the previous week, Prestige Consumer Healthcare had 19 more articles in the media than CorMedix. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 1 mentions for CorMedix. Prestige Consumer Healthcare's average media sentiment score of 1.38 beat CorMedix's score of 0.94 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Prestige Consumer Healthcare	Positive
CorMedix	Positive

Prestige Consumer Healthcare presently has a consensus price target of $70.75, suggesting a potential upside of 34.81%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 80.72%. Given CorMedix's stronger consensus rating and higher probable upside, analysts plainly believe CorMedix is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Prestige Consumer Healthcare has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Prestige Consumer Healthcare and CorMedix tied by winning 8 of the 16 factors compared between the two stocks.

How does CorMedix compare to Bausch Health Cos?

CorMedix (NASDAQ:CRMD) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

CorMedix has a net margin of 40.49% compared to Bausch Health Cos' net margin of -10.12%. CorMedix's return on equity of 40.52% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Bausch Health Cos	-10.12%	-561.95%	6.31%

In the previous week, Bausch Health Cos had 7 more articles in the media than CorMedix. MarketBeat recorded 8 mentions for Bausch Health Cos and 1 mentions for CorMedix. Bausch Health Cos' average media sentiment score of 1.15 beat CorMedix's score of 0.94 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Positive
Bausch Health Cos	Positive

CorMedix has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

CorMedix has higher earnings, but lower revenue than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.08	$163.05M	$2.14	3.88
Bausch Health Cos	$10.27B	0.23	$157M	-$2.96	N/A

CorMedix presently has a consensus price target of $15.00, suggesting a potential upside of 80.72%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 26.78%. Given CorMedix's stronger consensus rating and higher possible upside, equities research analysts plainly believe CorMedix is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CorMedix beats Bausch Health Cos on 11 of the 16 factors compared between the two stocks.

How does CorMedix compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

CorMedix has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
CorMedix	$311.71M	2.08	$163.05M	$2.14	3.88

Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

In the previous week, Rapport Therapeutics had 8 more articles in the media than CorMedix. MarketBeat recorded 9 mentions for Rapport Therapeutics and 1 mentions for CorMedix. CorMedix's average media sentiment score of 0.94 beat Rapport Therapeutics' score of 0.86 indicating that CorMedix is being referred to more favorably in the news media.

Company	Overall Sentiment
Rapport Therapeutics	Positive
CorMedix	Positive

CorMedix has a net margin of 40.49% compared to Rapport Therapeutics' net margin of 0.00%. CorMedix's return on equity of 40.52% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
CorMedix	40.49%	40.52%	20.61%

Rapport Therapeutics presently has a consensus price target of $62.86, indicating a potential upside of 28.88%. CorMedix has a consensus price target of $15.00, indicating a potential upside of 80.72%. Given CorMedix's higher probable upside, analysts plainly believe CorMedix is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

34.2% of CorMedix shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CorMedix beats Rapport Therapeutics on 11 of the 16 factors compared between the two stocks.

How does CorMedix compare to Urogen Pharma?

Urogen Pharma (NASDAQ:URGN) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

CorMedix has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	19.42	-$153.49M	-$1.98	N/A
CorMedix	$311.71M	2.08	$163.05M	$2.14	3.88

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Urogen Pharma presently has a consensus price target of $50.38, suggesting a potential upside of 15.49%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 80.72%. Given CorMedix's higher probable upside, analysts plainly believe CorMedix is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Urogen Pharma had 12 more articles in the media than CorMedix. MarketBeat recorded 13 mentions for Urogen Pharma and 1 mentions for CorMedix. Urogen Pharma's average media sentiment score of 1.26 beat CorMedix's score of 0.94 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Urogen Pharma	Positive
CorMedix	Positive

CorMedix has a net margin of 40.49% compared to Urogen Pharma's net margin of -51.73%. CorMedix's return on equity of 40.52% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
CorMedix	40.49%	40.52%	20.61%

Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Summary

Urogen Pharma beats CorMedix on 9 of the 17 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRMD vs. The Competition

Export

Metric	CorMedix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$647.72M	$12.21B	$7.24B	$12.93B
Dividend Yield	N/A	2.62%	2.54%	11.02%
P/E Ratio	3.88	780.29	271.50	25.41
Price / Sales	2.08	756.07	624.07	96.99
Price / Cash	4.06	95.73	79.29	54.21
Price / Book	1.40	11.93	12.95	6.14
Net Income	$163.05M	$2.81B	$3.46B	$347.93M
7 Day Performance	1.22%	0.52%	-0.11%	-0.78%
1 Month Performance	15.44%	6.37%	8.32%	5.60%
1 Year Performance	-44.03%	6.09%	24.64%	15.64%

CorMedix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRMD CorMedix	2.1764 of 5 stars	$8.30 -0.1%	$15.00 +80.7%	-42.2%	$647.72M	$311.71M	3.88	30
OCUL Ocular Therapeutix	2.9473 of 5 stars	$10.78 -2.7%	$25.75 +138.9%	-17.3%	$2.43B	$51.95M	N/A	230	Insider Trade
PBH Prestige Consumer Healthcare	3.4992 of 5 stars	$51.99 +1.3%	$70.75 +36.1%	-22.1%	$2.43B	$1.09B	14.56	540	Trending News Analyst Revision
BHC Bausch Health Cos	3.1787 of 5 stars	$6.69 +3.8%	$8.00 +19.7%	-11.9%	$2.41B	$10.27B	N/A	20,300
RAPP Rapport Therapeutics	3.2158 of 5 stars	$49.33 +2.3%	$62.86 +27.4%	+190.3%	$2.31B	N/A	N/A	N/A	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRMD) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Competitors

CRMD vs. OCUL, PBH, BHC, RAPP, and URGN

How does CorMedix compare to Ocular Therapeutix?

Summary

How does CorMedix compare to Prestige Consumer Healthcare?

Summary

How does CorMedix compare to Bausch Health Cos?

Summary

How does CorMedix compare to Rapport Therapeutics?

Summary

How does CorMedix compare to Urogen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Competitors

CRMD vs. OCUL, PBH, BHC, RAPP, and URGN

How does CorMedix compare to Ocular Therapeutix?

Which has more volatility & risk, CRMD or OCUL?

Do institutionals & insiders believe in CRMD or OCUL?

Which has preferable valuation & earnings, CRMD or OCUL?

Is CRMD or OCUL more profitable?

Do analysts recommend CRMD or OCUL?

Does the media refer more to CRMD or OCUL?

Summary

How does CorMedix compare to Prestige Consumer Healthcare?

Which has preferable valuation & earnings, PBH or CRMD?

Is PBH or CRMD more profitable?

Does the media prefer PBH or CRMD?

Do analysts rate PBH or CRMD?

Which has more risk and volatility, PBH or CRMD?

Do insiders and institutionals hold more shares of PBH or CRMD?

Summary

How does CorMedix compare to Bausch Health Cos?

Is CRMD or BHC more profitable?

Does the media prefer CRMD or BHC?

Which has more risk & volatility, CRMD or BHC?

Which has better earnings & valuation, CRMD or BHC?

Do analysts recommend CRMD or BHC?

Do insiders and institutionals hold more shares of CRMD or BHC?

Summary

How does CorMedix compare to Rapport Therapeutics?

Which has higher valuation & earnings, RAPP or CRMD?

Which has more risk & volatility, RAPP or CRMD?

Does the media prefer RAPP or CRMD?

Is RAPP or CRMD more profitable?

Do analysts rate RAPP or CRMD?

Do insiders & institutionals believe in RAPP or CRMD?

Summary

How does CorMedix compare to Urogen Pharma?

Which has stronger earnings and valuation, URGN or CRMD?

Do institutionals & insiders hold more shares of URGN or CRMD?

Do analysts prefer URGN or CRMD?

Does the media refer more to URGN or CRMD?

Is URGN or CRMD more profitable?

Which has more volatility & risk, URGN or CRMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools